EGFR and non-small cell lung carcinoma: Evaluation of key driver mutations, such as those found in the genes encoding EGFR, anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1), has now become routine practice in the diagnostic pipeline of individuals with advanced non-small cell lung cancer (NSCLC).